Skip to main content Help with accessibility Skip to main navigation

RIVAROXABAN 2.5mg tablets (Xarelto®▼) for Acute Coronary Syndrome

CCG Approval Status:

Date Added: 24 - May - 2017
Body System:
Amber initiated

The Pan Mersey Area Prescribing Committee recommends the prescribing of Rivaroxaban 2.5mg tablets (Xarelto®▼) following specialist initiation for preventing adverse outcomes after acute management of acute coronary syndrome in accordance with NICE TA335.